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Abstract 
In people with multiple sclerosis MS, the spinal cord is the structure most commonly 
affected by clinically detectable pathology at presentation, and a key part of the central 
nervous system involved in chronic disease deterioration. Indices, such as the spinal cord 
cross-sectional area at the level C2 have been developed as tools to predict future disability, 
and - by inference - axonal loss. However, this and other histo-pathological correlates of 
spinal cord magnetic resonance imaging (MRI) changes in MS remain incompletely 
understood. In recent years, there has been a surge of interest in developing quantitative 
MRI tools to measure specific tissue features, including axonal density, myelin content, 
neurite density and orientation, among others, with an emphasis on the spinal cord. 
Quantitative MRI techniques including T1 and T2, magnetisation transfer and a number of 
diffusion-derived indices have all been applied to MS spinal cord. Particularly diffusion-
based MRI techniques combined with microscopic resolution achievable using high 
magnetic field scanners enable a new level of anatomical detail and quantification of indices 
that are clinically meaningful. 
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Introduction 
In multiple sclerosis (MS), it is the spinal cord that is most commonly affected by clinically 
detectable pathology at presentation (Mowry et al., 2009; Katz Sand, 2015). Lesions in the 
spinal cord suggestive of demyelination have been shown to predict a definitive diagnosis of 
MS in patients with radiologically isolated, as well as clinically isolated, syndromes (Okuda et 
al., 2011) (Arrambide et al., 2017), and more severe disability (Brownlee et al., 2017) 
(Arrambide et al., 2017). And as MS evolves over time, much of the permanent and 
deteriorating disability in people with MS affects lower body functions, including lack of 
sphincter control, sexual dysfunction, and impaired leg movement and coordination, 
resembling the clinical syndrome of progressive myelopathy (Giovannoni et al., 2017; 
Kremenchutzky et al., 2006; McDonald and Compston, 2006; Kearney et al., 2015). 
 
It is therefore not surprising that the pathological manifestations of MS in the spinal cord 
have attracted renewed interest, including attempts to better visualise and quantify 
histological changes non-invasively using magnetic resonance imaging (MRI). Combining MRI 
with (quantitative) histology enables investigation of fundamental associations between 
tissue features with clinical relevance, such as the grey and white matter (Schlaeger et al., 
2014), and the cell types affected by disease, including the degree of tissue loss measured 
using volumetric MRI (Losseff et al., 1996), and the microscopic changes underlying this loss. 
Evidence suggests results obtained using brain samples cannot be directly translated to the 
spinal cord (McDowell et al., 2014).  
 
In this paper, we will review the pathological features of MS currently detectable on MRI of 
the spinal cord, with an emphasis on neuro-axonal loss, and on studies correlating MRI with 
histology. Recent pathological findings spell the need for further research into the spinal 
cord network and its destruction by MS. This work builds and expands on a recent topical 
review (Schmierer et al., 2018). 
 
MS lesions in the spinal cord 
After it had been recognized by the early 1980s that MRI exceeds the sensitivity of 
computed tomography not only of the brain (Young et al., 1981) but also of the spinal cord 
in detecting parenchymal lesions (Earnest et al., 1985), the first study directly correlating T2 
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weighted (T2W) MRI with MS lesions was published in 1994 when the case of a woman who 
died of MS at the age of 37 was reported, and imaging appearance correlated with histology 
(Nagao et al., 1994). A series of 59 spinal cord samples from 19 cases of MS and three 
controls were subsequently investigated using proton density (PD) weighted MRI at two 
different field strengths (1 and 4.7 Tesla) (Nijeholt et al., 2001). Correlation of MRI with 
histology in a proportion of the cases examined confirmed excellent visual match between 
lesions detected using histology and MRI at either field strength. Importantly, scans 
acquired at 4.7T additionally revealed a distinction between clearly demarcated lesions and 
rather diffuse changes, suggesting Wallerian (or retrograde) degeneration as a result of 
axonal transection in lesions (Trapp et al., 1998) (Nijeholt et al., 2001) (Dziedzic et al., 2010). 
 
Gilmore and co-workers were the first to shift the focus of correlative MRI-pathology studies 
on lesions affecting the spinal cord grey matter (Gilmore et al., 2009/1). Using a 4.7T 
scanner, PD MRI was acquired in cord samples of 11 pwMS and two controls. Following MRI 
acquisition, samples were dissected and immuno-stained for myelin basic protein. N= 40 
‘white matter only’ lesions, 55 mixed (white/grey matter) lesions, and one ‘grey matter only’ 
lesion were detected on PD MRI. Separating white and grey matter proportions of mixed 
lesions, 87% of histologically confirmed areas of white matter, and 73% of grey matter 
demyelination were detected using MRI, i.e. significantly more than in the neocortex 
(Geurts et al., 2011), where partial volume effects, among others, adversely affect their 
detection (Gilmore et al., 2009/1; Schmierer et al., 2010). 
 
Axonal loss in lesions and beyond 
Significant axonal loss takes place in the MS spinal cord, degree of which appears most 
strongly associated with the duration of the disease. A recent study reported reduction of 
axonal density in the cortico-spinal tracts by 57–62% across all cord levels after a mean 
disease duration of 29 years (Petrova et al., 2018), confirming earlier studies using tissue 
from pwMS with similar disease duration (Bjartmar et al., 2000; Tallantyre et al., 2009), 
whilst studies of material with shorter disease duration reported less pronounced axonal 
loss (Ganter et al., 1999; DeLuca et al., 2004). In line with this observation, axonal loss (be it 
within or beyond the margins of MS lesions (Bjartmar et al., 2000; Dziedzic et al., 2010)) is 
considered a major contributor to the relentless accrual of disability in pwMS over time. 
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Separating the effects on MRI indices of inflammation and demyelination on the one, and 
axonal damage and loss on the other hand, remains challenging. Whilst in 2001 Nijeholt and 
co-workers highlighted the close relationship between areas of high signal on T2W MRI with 
the extent of demyelination (Nijeholt et al., 2001), a subsequent study by the same group 
described considerable T2W MRI signal abnormalities in cord tissue not affected by lesions 
(non-lesional cord tissue) yet significant - and seemingly lesion-independent - axonal loss 
(Bergers et al., 2002). Of note, the authors did not control for remote effects on axonal loss 
of lesions along the pathway examined, which have been shown to be of importance when 
examining the relationship between inflammation, demyelination and axonal loss (Petrova 
et al., 2018). 
 
Magnetisation transfer 
Given the nonspecific nature of PD and T2 weighted MRI, a range of quantitative MR 
techniques including magnetisation transfer (MT) (Lema et al., 2017), diffusion (Cohen et al., 
2017) (Stikov et al., 2015) and spectroscopic metabolite concentration (albeit not in post 
mortem samples) have been used to try and improve detection and quantification of 
microstructural changes in the MS spinal cord (Gass et al., 2015). MT is a process by which 
macromolecular protons (for example, in myelin bi-phospholipid layers) and water protons 
(for example, in cerebro-spinal fluid) exchange magnetisation when exposed to an external 
magnetic field and a radio frequency saturation pulse. Changes in MT can be quantified and 
enable inferences about the underlying macromolecular content and structure (Tozer et al., 
2003). 
 
A number of MT indices has been explored in post mortem MS brain (van Waesberghe et al., 
1999; Barkhof et al., 2003; Schmierer et al., 2004, 2007), where they were shown to be 
primarily associated with myelin, though inflammation, oedema (Vavasour et al., 2011) and 
- particularly in NLSC - axonal loss (Petzold et al., 2011) also contribute. The strong 
association of MT, as well as T1 and T2 relaxation times, with myelin was confirmed in a 
study by Bot and co-workers on cervical spinal cord (Bot et al., 2004); and similar results 
were reported by Mottershead and co-workers in their study of spinal cord specimens 
employing a small bore high magnetic field (7T) scanner (Mottershead et al., 2003). The 
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latter study also highlighted an important issue when trying to separate MRI indices for 
axonal density and myelin content: that these tissue features themselves are quite strongly 
correlated (here, r= 0.67, p<0.0001) (Mottershead et al., 2003).  
 
Diffusion 
The strong association between changes in myelin and axons in a demyelinating disease like 
MS was also an important challenge for experiments using diffusion MRI. Work in animal 
models suggested the assessment of the directionality of diffusion (axial, radial) might 
enable more reliable non-invasive quantification of myelin versus axonal damage and loss in 
the CNS (Song et al., 2005). However, the apparently clear separation in the model proved 
difficult to reproduce in the human disease MS. Klawiter and coworkers applied DTI to post 
mortem spinal cord from nine pwMS and five control subjects using a 4.7T system (Klawiter 
et al., 2011). They placed regions of interest in areas semi-quantitatively graded as normally 
myelinated, mildly (<50%) and moderate-severely (>50%) demyelinated. Increasing radial 
diffusion (Drad) values were associated with the degree of demyelination but so was the 
extent of axonal loss, whilst axial diffusion (Dax), radial diffusivity and relative anisotropy did 
not predict axonal density in isolation. Analysis of myelin and axonal count simultaneously 
indicated that both tissue features contributed independently to changes in radial 
diffusivity, relative anisotropy and MD (Klawiter et al., 2011). The study by Mottershead and 
co-workers using a 7 Tesla MRI system also reported diffusion data. The ‘diffusion standard 
deviation index’ (SDI), a measure of anisotropy, was calculated after images had been 
acquired at two different diffusion gradient strengths. Moderate correlation emerged 
between the SDI and axonal count (r= 0.61, p<0.001) as well as myelin content (r= 0.51, 
p<0.001). 
 
Since single diffusion tensor models did not reliably enable extraction of indices specific to 
axonal damage and loss, more complex set-ups have recently combined multiple diffusion 
tensors for this purpose, such as diffusion basis spectrum imaging (DBSI) (Wang et al., 2011). 
DBSI models myelinated and unmyelinated axons as anisotropic diffusion tensors, and cells 
and oedema/extracellular space as isotropic diffusion tensors. Quantitative histological 
analysis of post mortem MS cervical spinal cord specimens (n=3) suggested that DBSI-
determined indices of cellularity, axons and myelin acquired on a small bore 4.7T magnet 
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are closely associated with those pathologies identified and quantified by conventional 
histology (Wang et al., 2015).  
 
Another promising diffusion-based attempt at increasing specificity for tissue components 
and their injury by MS is neurite orientation dispersion and density imaging (NODDI) 
(Jespersen et al., 2012; Zhang et al., 2012). An index of orientation dispersion is defined to 
characterize the angular variation of neurites. NODDI has been used both in vivo as well as 
for validation experiments on spinal cord samples including MS and control tissue (Grussu et 
al., 2017), By et la. 2016). Strong correlation was detected between a quantitative histology 
index defined as “circular variance” (CV) and the NODDI derived variable “orientation 
dispersion index” (ODI), suggesting ODI may provide a non-invasive marker of CV (Grussu et 
al., 2016). Comparison with more conventional DTI metrics such as mean diffusivity, 
fractional anisotropy, Dax and Drad  suggest NODDI may indeed provide more precise 
estimates of the complexity of dendrites and axons (Grussu et al., 2017). 
 
The envelope of non-invasive visualisation and quantification of spinal cord pathology has 
recently been pushed further by successful acquisition of 3D anatomic image data (50 μm 
isotropic resolution) alongside 100 μm isotropic resolution diffusion data of an entire spinal 
cord (Calabrese et al., 2018) (figure 1). This was made possible by a multi-segment 
acquisition lasting 280 h, and automated image segment composition. The ability to acquire 
such datasets provides a platform for spinal cord lesion detection, automated volumetric 
grey matter segmentation, and quantitative spinal cord morphometry including estimates of 
cross sectional dimensions and grey matter fraction throughout the length of the cord 
(figure 2) (Calabrese et al., 2018). 
 
The novel techniques outlined above, including high resolution MR microscopy (Calabrese et 
al., 2018), DBSI (Wang et al., 2011, 2015) and NODDI are likely to offer advantages in terms 
of tissue specificity which, in the case of NODDI, notably include indices to assess spinal cord 
grey matter (Zhang et al., 2012; Grussu et al., 2015, 2017). If preliminary reports can be 
confirmed, and reproducibility further improved (Grussu et al., 2015; Tanguy Duval et al., 
2017), these techniques may offer significant steps in the quest for accurate in vivo 
assessment of spinal cord pathology in MS, perhaps in combination with other techniques, 
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such as MT or multi-component relaxometry (Tanguy Duval et al., 2017). It is encouraging 
that several initiatives to improve the standardisation of spinal cord MRI analysis have gone 
underway that will likely facilitate MRI-pathology studies yet further thereby enabling more 
rapid validation of new techniques in the future (Grussu, n.d.; De Leener et al., 2017). 
 
Spinal cord cross-sectional area as a proxy of axonal loss? 
Whilst the quantification of tissue “microstructure” using quantitative MRI is of significant 
interest to potentially better understand the pathophysiology of MS in the spinal cord, none 
of the above mentioned techniques have entered the realm of clinical trials, let alone clinical 
practice, where the detection of lesions using conventional MRI techniques continues to 
dominate. However, limitations in (i) the association between demyelinating lesions and 
axonal loss and (ii) lesion detection in the MS spinal cord due to technical artefacts, have 
highlighted the need for alternative indices with potential to be robust predictors of axonal 
damage and loss. 
 
Since the seminal study by Losseff and coworkers (Losseff et al., 1996) more than 20 years 
ago, numerous clinical studies underpinned the correlation between a reduction of the 
spinal cord cross-sectional area (CSA) and disability (Losseff et al., 1996; Kearney et al., 
2015; Aymerich et al., 2018). CSA loss has also been applied as an outcome in a small 
number of clinical trials (Kapoor et al., 2010; Rice et al., 2015), and various methods have 
been used to measure it including semi-automated edge finding (Lin et al., 2003), edge 
detection with partial volume corrections (Tench et al. 2005), voxelwise mapping (Rocca et 
al., 2013), an active surface model (Kearney et al., 2014) and semi-automated cord volume 
estimation techniques (Lukas et al., 2015).  
 
Based on experimental data, CSA loss - and its association with clinical disease progression - 
has long been considered as a key substrate of axonal degeneration. However, recent data 
suggest the macro-/microscopic relationship between CSA and nerve fibre loss is not as 
straightforward (Petrova et al., 2018).  
 
Following preliminary work on a small number of specimens by Bjartmar and co-workers 
(Bjartmar et al., 2000), a recent study comprehensively sampled spinal cords of 13 pwMS 
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with a mean disease duration of 29 years, and five healthy controls to assess the association 
between axonal density and CSA . Using just under of 400 tissue blocks a reduction of the 
CSA of 19-24% was detected at all (cervical, thoracic and lumbar) levels with white and grey 
matter areas contributing equally across levels. However, compared to controls axonal 
density was reduced by 57-62%. And whilst disease duration was a predictor of reduced 
axonal density, CSA was not, and neither were separate indices of proportional grey or 
white matter area (Petrova et al., 2018).  
 
This surprising lack of correlation evidently challenges the concept of CSA shrinkage being a 
predictor of axonal loss, and other factors had to be considered, including “space filling” 
through gliosis, since this would be expected to counteract the area reducing effect of 
axonal loss (Bjartmar et al., 2000; Hampton et al., 2013). Since both grey and white matter 
contributed equally to the reduction of CSA, it is unlikely that long tract systems (cortico-
spinal, dorsal ascending, and others) are exclusively contributing to the sum total CSA 
change. In line with this finding, it is has been suggested that neuronal shrinkage and loss, 
and a reduction in neurite orientation disp rsion (Grussu et al., 2017) may contribute to 
both disability and loss of CSA (Christopher P. Gilmore et al., 2009/2; Schirmer et al., 2009). 
Finally, based on synaptophysin immuno-staining, a substantial loss of synapses has recently 
been reported affecting both non-lesional and lesional cord grey matter. This loss was 
associated with grey matter area shrinkage (Petrova et al., 2016). Some (or all) of these 
results may also explain that reported associations between CSA and disability have in a 
number of recent studies been rather moderate (Schlaeger et al., 2014; Aymerich et al., 
2018).  
 
Improving the non-invasive prediction of tissue changes in MS - is MR microscopy 
realistic? 
The pathology of MS is complex, and its aetiology and pathogenesis on the microstructural 
level remain incompletely understood. It is, thus, not surprising that attempts at MRI 
quantification of specific tissue features (axons, myelination status, microglial activation, 
gliosis, etc) are challenging.  
Until quite recently, key MRI-pathology studies of the spinal cord made hardly any reference 
to the grey matter which, similar to its importance in the brain (Carassiti et al., 2018), is a 
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likely key factor for the clinical manifestations of MS. Long spinal cord white matter tract 
systems, such as the cortico-spinal and the dorsal ascending (sensory) tract systems, with 
their largely longitudinal orientation are obviously ideal candidates to model new 
techniques including attempts at measuring the g-ratio in vivo (Stikov et al., 2015; Campbell 
et al., 2017; T. Duval et al., 2017). However, when looking at MS as a disease, and the need 
for pwMS, their health care professionals and scientists to better understand and manage 
their condition, it is important to consider the spinal cord as a functional network with 
millions of perpendicular connections that are damaged in MS and impact on function 
(Bourane et al., 2015; Grussu et al., 2016; Petrova et al., 2016). 
 
Given the importance of immune-mediated demyelination for the degree of axonal loss 
throughout MS (Montalban et al., 2017; Petrova et al., 2018), there is an ongoing need for 
further improved techniques to detect lesions across the length of the spinal cord, to be 
used as outcomes in trials of new compounds for the clinical management of pwMS 
(Giovannoni et al., 2015). This is particularly true against the backdrop of the poor 
prediction of disability based on lesions detected using conventional MRI techniques 
(Dekker et al., 2018). 
 
The recently developed toolboxes for both improved MRI and pathology measurement of 
spinal cord pathology provide exciting new opportunities to integrate the complexity of MS 
pathophysiology. The techniques used have come a long way including new standardised 
methods to map spinal cord MRI onto histology (and vice versa). In post mortem studies of 
the MS brain, this problem has been recognized for some time (Moore et al., 2000), and 
various techniques were subsequently developed to improve registration, including use of a 
stereotaxic frame (Schmierer et al., 2003; Bö et al., 2004), imaging the unfixed brain in situ 
with subsequent rescanning of the fixed tissue and use of customised cutting panels (Bö et 
al., 2004; Fisher et al., 2007), and most recently, the introduction of individually 
manufactured cutting panels using 3D printing technology (Luciano et al., 2016).  
 
Compared to the brain the spinal cord appears like a less challenging structure to match MRI 
with histology. However, the recently published systematic framework for histological 
quantification (Grussu et al., 2016) combined with landmark-guided co-registration and 
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high-resolution imaging (Calabrese et al., 2018) provide insights into how complex (and 
successful), new approaches to correlative MRI-pathology studies of post mortem spinal 
cord can be (Grussu et al., 2017), against the backdrop of a much stronger emphasis on 
histological quantification (optical density indices, stereology, orientation dispersion, etc.) 
(Schmierer et al., 2004; Grussu et al., 2016; Carassiti et al., 2018), over and above 
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Figure legends 
 
Figure 1:  
Magnetic resonance imaging (MRI) of an entire human spinal cord at the level of the central 
canal using a 7 Tesla small bore MR system. Techniques used included T2* weighted 
gradient echo (A) and diffusion-weighted MRI (B). The coloured image (C) represents a map 
of fractional anisotropy (directionality) derived from diffusion weighted imaging. 
Reproduced with permisson from Calabrese, et al. 2018. 
 
Figure 2:  
Multi-contrast axial magnetic resonance images of a human spinal cord at different levels. 
Contrasts include: T2*, T2* weighted gradient echo; B0, b=0 image from diffusion 
acquisition; DWI, isotropic diffusion weighted image; FA, fractional anisotropy; FAC, 
directionally colored fractional anisotropy. Reproduced with permisson from Calabrese, et 
al. 2018. 
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